3 results
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
Primary: - To evaluate differences in side effect profile of patients treated with focal or extended ablation performed with image-guided IRE for the ablation of prostate carcinoma. - To evaluate differences in quality of life of patients treated…
To determine whether dapagliflozin is superior to placebo in reducing the incidence of the primary composite endpoint of kidney failure, hospitalization for heart failure, and all-cause mortality in the overall patient group, consisting of patients…